Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beyondspring Inc BYSI

Healthcare Biotechnology
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer... see more

Recent & Breaking News (NDAQ:BYSI)

BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney

GlobeNewswire July 14, 2021

BeyondSpring to Participate in the William Blair Biotech Focus Conference

GlobeNewswire July 8, 2021

BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin's Development Program in Anti-cancer Indications

GlobeNewswire June 17, 2021

BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update

GlobeNewswire June 16, 2021

BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021

GlobeNewswire June 11, 2021

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 10, 2021

BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting

GlobeNewswire June 8, 2021

BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 7, 2021

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

GlobeNewswire June 4, 2021

BeyondSpring Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

GlobeNewswire June 1, 2021

BeyondSpring to Present at the Jefferies Virtual Healthcare Conference on June 3, 2021

GlobeNewswire May 26, 2021

BeyondSpring Presents Phase 1 Data on the Anti-Cancer Effect of Plinabulin in Combination with Checkpoint Inhibitors in SCLC at the American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 24, 2021

BeyondSpring to Present at the Bank of America Securities 2021 Health Care Conference on May 13, 2021

GlobeNewswire May 10, 2021

BeyondSpring Files 2020 Annual Report on Form 20-F

GlobeNewswire April 30, 2021

BeyondSpring Announces Fourth Quarter and Year End 2020 Financial Results and Provides a Corporate Update

GlobeNewswire April 30, 2021

BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire April 28, 2021

BeyondSpring to Announce Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call on Friday, April 30, 2021

GlobeNewswire April 27, 2021

BeyondSpring Announces Submission of New Drug Application to U.S. FDA and China NMPA for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

GlobeNewswire March 31, 2021

BeyondSpring Hosting Key Opinion Leader Webinar on Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia

GlobeNewswire March 11, 2021

UPDATE -- BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021

GlobeNewswire December 29, 2020